Anders Rabbe CEO Of Isofol Medical Discusses Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS .
Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS
By Editor
Advertisement
By Editor
Anders Rabbe CEO Of Isofol Medical Discusses Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS .